The γδ T-cell receptor repertoire is reconstituted in HIV patients after prolonged antiretroviral therapy

AIDS

Volumn 27, Issue 10, 2013, Pages 1557-1562

  Chaudhry, Suchita ^a   Cairo, Cristiana ^a   Venturi, Vanessa ^b   Pauza, C David ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; T LYMPHOCYTE RECEPTOR;

ANTIGEN ANTIBODY REACTION; ARTICLE; BIOINFORMATICS; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; GAMMA DELTA T LYMPHOCYTE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIREMIA;

ANTI-RETROVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; TREATMENT OUTCOME;

EID: 84879110636     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283611888     Document Type: Article

References (34)

1. Enders PJ, Yin C, Martini F, Evans PS, Propp N, Poccia F, et al. HIV-mediated gammadelta T cell depletion is specific for Vgamma2R cells expressing the Jgamma1.2 segment. AIDS Res Human Retrovirus 2003; 19:21-29.
2. Hebbeler AM, Propp N, Cairo C, Li H, Cummings JS, Jacobson LP, et al. Failure to restore the Vgamma2-Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin Immunol 2008; 128:349-357.
3. Li H, Pauza CD. HIV envelope-mediated, CCR5/alpha4beta7-dependent killing of CD4-negative gammadelta T cells which are lost during progression to AIDS. Blood 2011; 118:5824-5831.
4. Bordon J, Evans PS, Propp N, Davis CE Jr, Redfield RR, Pauza CD. Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis 2004; 189:1482-1486.
5. Sajadi MM, Heredia A, Le N, Constantine NT, Redfield RR. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 2007; 21:517-519.
6. Riedel DJ, Sajadi MM, Armstrong CL, Cummings JS, Cairo C, Redfield RR, et al. Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS 2009; 23:1955-1964.
7. Pauza CD, Riedel DJ, Gilliam BL, Redfield RR. Targeting gammadelta T cells for immunotherapy of HIV disease. Future Virol 2011; 6:73-84.
8. Boudova S, Li H, Sajadi MM, Redfield RR, Pauza CD. Impact of persistent HIV replication on CD4 negative Vgamma2Vdelta2 T cells. J Infect Dis 2012; 205:1448-1455.
9. Morita CT, Beckman EM, Bukowski JF, Tanaka Y, Band H, Bloom BR, et al. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity 1995; 3:495-507.
10. Cairo C, Armstrong CL, Cummings JS, Deetz CO, Tan M, Lu C, et al. Impact of age, gender, and race on circulating gammadelta T cells. Human Immunol 2010; 71:968-975.
11. Venturi V, Price DA, Douek DC, Davenport MP. The molecular basis for public T-cell responses? Nature Rev Immunol 2008; 8:231-238.
12. Cummings JS, Cairo C, Armstrong C, Davis CE, Pauza CD. Impacts of HIV infection on Vgamma2Vdelta2 T cell pheno-type and function: a mechanism for reduced tumor immunity in AIDS. J Leukocyte Biol 2008; 84:371-379.
13. Venturi V, Kedzierska K, Turner SJ, Doherty PC, Davenport MP. Methods for comparing the diversity of samples of the T cell receptor repertoire. J Immunol Methods 2007; 321:182-195.
14. Venturi V, Kedzierska K, Tanaka MM, Turner SJ, Doherty PC, Davenport MP. Method for assessing the similarity between subsets of the T cell receptor repertoire. J Immunol Methods 2008; 329:67-80.
15. Bukowski JF, Morita CT, Brenner MB. Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 1999; 11:57-65.
16. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96:384-392.
17. Tanaka Y, Brenner MB, Bloom BR, Morita CT. Recognition of nonpeptide antigens by T cells. J Mol Med 1996; 74:223-231.
18. Hebbeler AM, Cairo C, Cummings JS, Pauza CD. Individual Vgamma2-Jgamma1.2R T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens. Cancer Immunol Immunother 2007; 56:819-829.
19. Lamb LS Jr, Lopez RD. gammadelta T cells: a new frontier for immunotherapy? Biol Blood Marrow Transplant 2005; 11:161-168.
20. Viey E, Laplace C, Escudier B. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for meta-static renal cell carcinoma. Expert Rev Anticancer Ther 2005; 5:973-986.
21. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4R T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
22. Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998; 12:F217-223.
23. Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian R, et al. Nadir CD4R T-cell count and numbers of CD28R CD4R T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003; 17:2015-2023.
24. Kaufmann GR, Zaunders JJ, Cunningham P, Kelleher AD, Grey P, Smith D, et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000; 14:2643-2651.
25. Renaud M, Katlama C, Mallet A, Calvez V, Carcelain G, Tubiana R, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999; 13:669-676.
26. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690-695.
27. Zhang L, Lewin SR, Markowitz M, Lin HH, Skulsky E, Karanicolas R, et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999; 190:725-732.
28. Yin L, Kou ZC, Rodriguez C, Hou W, Goodenow MM, Sleasman JW. Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents. Clin Vaccine Immunol 2009; 16:1293-1301.
29. Dik WA, Pike-Overzet K, Weerkamp F, de Ridder D, de Haas EF, Baert MR, et al. New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med 2005; 201:1715-1723.
30. Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, Delfraissy JF, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012; 55:291-300.
31. Poonia B, Pauza CD. Gamma delta T cells from HIVR donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Cytotherapy 2012; 14:173-181.
32. Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M, et al. Zoledronate-activated Vgamma9gammadelta T cell-based immunotherapy is feasible and restores the impairment of gammadelta T cells in patients with solid tumors. Cytotherapy 2011; 13:92-97.
33. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009; 58:31-38.
34. Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS 2009; 23:555-565.